The End Game

Hospitals are losing leverage on lab outreach faster than most CEOs realize. Melissa Butterworth breaks down why the window to sell, restructure, or renegotiate a hospital lab asset is closing—and what senior leaders need to ask before the market shifts again.With 27 years in the lab diagnostics industry, Melissa draws on a career that began in hospital outreach in Jacksonville and has tracked the sector’s biggest ownership changes ever since. She makes the case that lab operations are no longer a side conversation—they’re now part of the same strategic reset happening across the entire health system.You’ll discover: Why buyer appetite is shrinking as Labcorp, Quest, and other strategic players keep acquiring How consolidation is changing negotiation power for hospital CEOs and CFOs Why PAMA reimbursement pressure keeps eroding the value of standalone outreach programs What the latest transaction mix says about hospitals divesting at a much higher rate The four real options on the table: sell, joint venture, outsource, or reinvest internally Melissa also explains why the right answer is not always a sale. Sometimes the smartest move is to preserve optionality, but that only works if leadership knows what the asset is worth today and who is still buying.Essential listening for hospital executives, health system advisors, attorneys, CPAs, and wealth advisors who need to understand where lab value is headed before more doors quietly close.

AI is already changing lab diagnostics - but not where most people think. The real wins are happening in reimbursement, prior auth, claim support, data reporting, and clinical trial workflows, while the flashier promise of AI-assisted pathology is still moving much slower than the sales pitches suggest.Melissa Butterworth cuts through the hype and zeroes in on what lab leaders, hospital executives, and advisors need to know before signing on to another AI vendor promise. If you are trying to decide whether AI is a true operational partner or just the latest cost-centered buzzword, this episode gives you the signal inside the noise.You will hear why AI adoption is gaining traction fastest in the back office, where ROI is immediate and measurable, and why pharma and biotech-facing labs are using AI to streamline patient recruitment and sample handling. You will also hear where the technology is still stuck, what vendors often leave out about digital pathology, and why data privacy and governance need real answers, not marketing language.Melissa also breaks down the cultural barrier that can make or break an implementation: when hospital leadership treats the lab like a cost center instead of a strategic asset, even the smartest tools struggle to get funded, supported, and scaled. She explains how lab leaders can strengthen the business case, refine workflows around the tool, and communicate upward to the C-suite in a way that gets attention.If you are evaluating AI for a lab, advising a health system, or trying to understand where this technology is actually delivering value today, this is essential listening. The episode leaves you with a sharper framework for separating real progress from hype, and for asking the questions that matter before the budget is decided.

PAMA is not "fixed," and the next real hit to lab reimbursement is closer than most executives think. Melissa Butterworth breaks down why the 2027 cliff is still ahead, why another easy congressional rescue may be less likely than before, and what lab leaders need to do right now to protect revenue.The headline everyone heard was "delay." The more important story is what Congress actually pushed back, what remains scheduled for 2027, 2028, and 2029, and why the reporting window opening in 2026 matters far more than a temporary patch. Melissa explains the latest legislative changes, the shifting CBO scoring problem that makes another one-year delay harder to pass, and why the industry conversation has moved from "Will we get another rescue?" to "What happens if we don't?"You'll discover: What PAMA really is and how prior rounds of cuts removed billions from the lab industry Why the 2026 reporting window directly impacts 2027 Medicare rates How the pending cuts could reach up to 15% on more than 800 laboratory procedures What the Results Act would change if it becomes law Why modeling revenue exposure now is no longer optional for outreach labs, hospital labs, and clinical labs Melissa also walks through the practical stakes for advisors and lab executives, including how to prepare clients for the possibility that the safety net Congress has relied on seven times may not appear again. If you are responsible for lab revenue, reimbursement strategy, or client advisory conversations, this episode gives you the urgency and the framework to act before the next deadline hits. Melissa Butterworth is the host of Endgame Insiders on Your Side and a senior voice in the medical lab industry. She brings a clear-eyed, advisory perspective to one of the most urgent reimbursement issues facing labs today.Perfect for lab executives, outreach leaders, consultants, and anyone who needs to understand what PAMA really means for 2027 and beyond.

Melissa Butterworth discusses the potential pitfalls of outsourcing a laboratory, highlighting the importance of careful consideration and strategic planning. She emphasizes the need for hospital executives to ask critical questions before making the decision to outsource. Takeaways Outsourcing can solve real problems for systems that lack the scale to run a competitive lab alone. Hospital executives should consider the long-term implications and have a detailed operational plan for rebuilding in-house if the outsourcing relationship doesn't work out. Chapters 00:00 Introduction and Fun Fact 00:58 Becoming a Godmother and Return to the Episode 01:28 The Outsourcing Trap 01:55 Why Hospitals Outsource Labs 02:53 The Downstream Effects of Outsourcing 03:52 Costly Consequences of Poorly Structured Outsourcing 04:48 Critical Questions for Hospital Executives 06:14 Final Thoughts and Contact Information

In this episode of the End Game Podcast, host Melissa Butterworth discusses her personal journey in the laboratory diagnostic space and delves into the complexities of Alzheimer's disease. She highlights the current state of treatments, including anti-amyloid therapies, and emphasizes the importance of early diagnosis. The conversation shifts to lifestyle interventions that can support cognitive health, such as exercise, nutrition, and social engagement. Finally, Melissa encourages proactive approaches to improve the quality of life for those affected by Alzheimer's, urging listeners to seek community support and professional guidance.